Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MultiStem® cell therapy (invimestrocel) is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic fac...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 20, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs
Details : MultiStem® cell therapy (invimestrocel) is patented regenerative medicine product has shown ability to promote tissue repair and healing in a variety of ways, such as through production of therapeutic factors in response to signals of inflammation and t...
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment
Details : The TREASURE study is a placebo-controlled, double-blind, phase 2/3 trial designed to confirm the efficacy and safety of MultiStem (HLCM051) in treating patients with ischemic stroke.
Product Name : MultiStem
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 08, 2021
Lead Product(s) : Invimestrocel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Athersys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.
Product Name : HLCM051
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2020
Lead Product(s) : HLCM051
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HLCM051
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Healios to Enroll COVID-19 Patients in Phase II Off-the-Shelf Cell Therapy Program for ARDS
Details : HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.
Product Name : HLCM051
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : HLCM051
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable